These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 20683501)

  • 1. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
    Owen RT
    Drugs Today (Barc); 2010 Jul; 46(7):463-71. PubMed ID: 20683501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular paliperidone palmitate.
    Hoy SM; Scott LJ; Keating GM
    CNS Drugs; 2010 Mar; 24(3):227-44. PubMed ID: 20155997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
    Carter NJ
    Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
    Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M
    Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
    Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
    BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
    Samtani MN; Gopal S; Gassmann-Mayer C; Alphs L; Palumbo JM
    CNS Drugs; 2011 Oct; 25(10):829-45. PubMed ID: 21936586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
    Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G
    BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
    Alphs L; Benson C; Cheshire-Kinney K; Lindenmayer JP; Mao L; Rodriguez SC; Starr HL
    J Clin Psychiatry; 2015 May; 76(5):554-61. PubMed ID: 25938474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
    Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J
    J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
    Perry R; Wolberg J; DiCrescento S
    Am J Health Syst Pharm; 2012 Jan; 69(1):40-3. PubMed ID: 22180550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
    Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
    Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate].
    Morozova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2):85-8. PubMed ID: 22712069
    [No Abstract]   [Full Text] [Related]  

  • 18. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia.
    Alphs L; Mao L; Rodriguez SC; Hulihan J; Starr HL
    J Clin Psychiatry; 2014 Dec; 75(12):1388-93. PubMed ID: 25375367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
    Fleischhacker WW; Gopal S; Lane R; Gassmann-Mayer C; Lim P; Hough D; Remmerie B; Eerdekens M
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):107-18. PubMed ID: 21777507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.